i-net & LSNB Event “Aurealis Pharma: Bacteria-based multi-therapy and successful financing rounds”

Tue, 24.05.2016 @18:45
in Halle7/sichtbar blindekuh Basel
[add to iCal]


About the event

Please register through the event page here.

i-net & LSNB Event «Aurealis Pharma: Bacteria-based multi-therapy and successful financing rounds»

Foun­ded in Fin­land with head­quar­ters in Basel, Au­rea­lis Phar­ma has de­ve­l­o­ped a bac­te­ri­al bio­re­ac­tor, ap­p­lied lo­cal­ly, that pro­du­ces and se­cre­tes the­ra­peu­tic human pro­te­ins di­rect­ly into di­sea­sed tis­sue from pa­ti­ents. Their first pro­ducts are im­mu­no-the­ra­peu­tics tar­ge­ting chro­nic in­flam­ma­to­ry wounds and can­cer in­di­ca­ti­ons. The same tech­no­lo­gy can be ap­p­lied to other major unmet indications.

Au­rea­lis Phar­ma has in­iti­al­ly been fi­nan­ced by the foun­der group and a state owned Fin­nish VC (Finn­ve­ra) and re­cei­ved ad­di­tio­nal non-di­lu­ti­ve fun­ding from a go­vern­men­tal-ow­ned Fin­nish agen­cy (Tekes). Re­cent­ly, the com­pa­ny has re­lo­ca­ted their HQ to Basel to ad­van­ce their lead com­pound AUP16 towards cli­ni­cal de­ve­lop­ment. The move did also pro­vi­de ac­cess to the very ex­pe­ri­en­ced pri­va­te in­ves­tor base found in the re­gi­on. This has great­ly paid out, Au­rea­lis Phar­ma has been able to collect close to 5.5 mil­li­on CHF last fall, which came half from local pri­va­te in­ves­tors as well as half from non-di­lu­ti­ve fun­ding via Tekes.

This i-net & LSNB event in Basel on May 24th, 2016 (Halle 7, 19:00; door opening 18:45) will have Dirk Weber, Chief Me­di­cal Of­fi­cer of Au­rea­lis Phar­ma and ex­pe­ri­en­ced phar­ma in­dus­try pro­fes­sio­nal, tal­king about this story and sharing in­sights and learnings along the way, es­pe­cial­ly fo­cus­sing on in­cor­po­ra­ting the com­pa­ny in Swit­z­er­land and suc­cess­ful­ly com­ple­ting the last, bi­la­te­ral fi­nan­cing round.

About Dr. Dirk Weber
Dirk is an MD, PhD with ex­ten­si­ve ex­pe­ri­ence in glo­bal drug de­ve­lop­ment of an­ti-can­cer drugs.
He did on­co­lo­gy re­se­arch at George­town Uni­ver­si­ty, US, at the In­sti­tu­te of Ge­ne­ral Pa­tho­lo­gy at Uni­ver­si­ty of Kiel and at the Ivonex GmbH in Kiel, Ger­ma­ny. After that he held se­ni­or cli­ni­cal de­ve­lop­ment po­si­ti­ons at Merck Se­ro­no, No­var­tis Phar­ma and Ta­ke­da Phar­maceu­ti­cals. He has worked in ear­ly- and la­te-sta­ge cli­ni­cal de­ve­lop­ment pro­grams which in­clu­ded in­ter­ac­tions with all major re­gu­la­to­ry aut­ho­ri­ties, dos­sier filing and lead of sub­mis­si­on teams. Dirk also gai­ned ex­ten­si­ve ex­pe­ri­ence in the plan­ning and pre­pa­ra­ti­ons re­qui­red for se­veral com­mer­ci­al pro­duct laun­ches globally.

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.